Who Makes Ibogaine? Producers And Developers

Most modern commercial ibogaine hydrochloride is discussed as a semi-synthetic product. The starting botanical raw material is often Voacanga africana, a tree whose bark and seeds contain voacangine, an alkaloid that can support a more scalable supply chain than repeated harvest of iboga root bark.

In a typical semi-synthetic route, voacangine is isolated through extraction and purification, then converted through chemical synthesis. Demethoxycarbonylation and demethylation are commonly described steps: the former involves decarboxylation-related chemistry, while the latter adjusts the molecular structure toward ibogaine. Each chemical precursor, reaction condition, and purification step affects API purity.

This does not make the result unregulated. Semi-synthetic ibogaine still requires batch testing, quality control, and a documented synthetic route. Manufacturers use high-performance liquid chromatography, commonly shortened to HPLC, to quantify target material and relevant impurities; mass spectrometry adds identity and contaminant evidence.

A company announcement on U.S. ibogaine manufacturing and Benuvia operations illustrates how publicly described programs frame licensed production around pharmaceutical-grade material rather than informal extraction. Such claims remain company-reported unless independently verified through regulatory documentation.

Trade listings can show multiple potential suppliers, but a directory is not proof of licensure, GMP status, or suitability for clinical trials. The ibogaine hydrochloride manufacturer listings are therefore best treated as market leads that require facility-level verification.

Tabernanthe iboga is central to the history of ibogaine, but it is difficult to treat as an industrial feedstock. The rain forest shrub grows slowly and may take five to seven years to yield root bark with viable alkaloid concentrations. Harvesting root bark can kill or severely harm the plant, placing extraction in direct tension with sustainability.

That pressure is especially important in Gabon and across Central Africa, where Tabernanthe iboga is culturally significant to Bwiti communities. Gabon declared Tabernanthe iboga a protected national treasure in 2000. International movement of genetic and biological materials also brings the Nagoya Protocol into view, including benefit-sharing and consent questions.

The Convention on Biological Diversity’s access and benefit-sharing information provides the broader official context for the Nagoya Protocol. For producers, regulatory compliance is not only a controlled-substance issue; it is also a sourcing, conservation, and community-accountability issue.

Natural extraction may produce total alkaloid material or an iboga extract containing multiple compounds. Pure ibogaine hydrochloride, by contrast, is a defined active pharmaceutical ingredient intended to meet a specific identity and purity specification. The difference determines how reliably a dose can be characterized and whether a batch can plausibly support clinical supply.

Overharvesting, weak documentation, and variable botanical raw material create risks for both conservation and quality control. A sustainable supply chain needs traceability from collection through extraction, not just a statement that a product is “natural.”

Specialized contract development and manufacturing organizations, or CDMOs, sit between a research sponsor and a finished investigational drug product. Contract manufacturing can include process development, analytical method validation, GMP API manufacture, stability work, formulation, packaging, and release testing.

Dalton Pharma Services and Purisys are frequently named in discussions of controlled-substance manufacturing capability. Dalton Pharma Services and Purisys should not be treated as interchangeable claims of current ibogaine production without a specific public record, but the CDMO model clarifies what pharmaceutical-grade clinical supply requires.

Good manufacturing practice is more than clean equipment. GMP requires controlled procedures, trained personnel, documented deviations, traceable raw materials, validated analytical methods, and quality control release criteria. Good manufacturing practice also means an API must be supported by records that can withstand regulatory review.

Because ibogaine can create cardiotoxicity concerns, purity is not a cosmetic specification. hERG potassium-channel inhibition can contribute to QT prolongation, and QT prolongation is part of why cardiovascular screening, concomitant-medication review, and dose control appear in clinical protocols. The FDA’s drug development and interaction resources provide a useful official frame for why pharmacology and safety assessment cannot be separated from manufacturing decisions.

Recent reporting has highlighted a strategic supply relationship involving Psyence and a DEA-registered partner; the announced pharmaceutical-grade ibogaine manufacturing partnership is a company disclosure, not evidence of FDA approval.

Similarly, the filed statement on a manufacturing collaboration is relevant for evaluating the stated development path, while public claims should still be read alongside the actual status of clinical trials and regulatory permissions.

The development landscape includes companies working with ibogaine itself, noribogaine, oral formulations, and analog compounds. DemeRx has partnered with Atai Life Sciences around DMX-1001, an oral ibogaine formulation being advanced for opioid use disorder. DemeRx and Atai Life Sciences represent sponsors and developers, not necessarily the CDMO that performs each manufacturing operation.

MindMed previously developed 18-MC, also called 18-methoxycoronaridine. 18-MC is a synthetic congener inspired by the ibogaine scaffold, designed to seek addiction treatment activity while reducing hallucinogenic effects and cardiac safety liabilities. The 18-MC program demonstrates why medicinal chemistry and CNS research may become as important as plant extraction.

Gilgamesh Pharmaceuticals and Delix Therapeutics are also associated with neuroplastogen-focused approaches to novel chemical entities. Gilgamesh Pharmaceuticals and Delix Therapeutics are pursuing derivatives and analog design rather than simply scaling conventional ibogaine. Their work illustrates a broader psychedelic medicine strategy: use receptor binding and synthetic chemistry to create a potentially different safety profile.

The official Gilgamesh Pharmaceuticals development overview describes the company’s focus in this adjacent neuropsychiatric drug-development space. An analog is not interchangeable with ibogaine, and it should not be presented as clinically proven merely because it shares a structural inspiration.

For context on classification, the ibogaine drug classification explainer summarizes why legal treatment of the parent compound varies across jurisdictions. Classification affects controlled substance scheduling, import permissions, clinical supply planning, and the evidence needed for regulatory compliance.

The central scientific objective for many next-generation programs is to preserve therapeutic potential without reproducing ibogaine’s full risk profile. Researchers are examining whether an analog, noribogaine-related approach, or 18-MC-like molecule can influence addiction-relevant pathways with less cardiotoxicity, less QT prolongation, and a shorter acute experience.

That objective remains investigational. Opioid use disorder is a serious condition, and withdrawal symptoms can be medically consequential. No manufacturing improvement alone can establish efficacy for addiction treatment; clinical trials, patient selection, dose design, and independent evidence all remain necessary.

The National Institute on Drug Abuse maintains an official overview of opioid research that places opioid use disorder in its public-health context. It is a reminder that an API’s technical quality and a medicine’s demonstrated benefit are separate questions.

Companies sometimes characterize their programs in investor or trade coverage. For example, pharmaceutical industry coverage of ibogaine development may identify announced strategic activity, but announcements should be distinguished from peer-reviewed results or an FDA decision.

To make pharmaceutical-grade ibogaine for a study, a manufacturer needs more than a reliable synthesis. GMP, controlled-substance authorization, quality control, and a chain of custody must align. The active pharmaceutical ingredient must be tested for identity, purity, potency, residual solvents, and relevant contaminants; HPLC and high-performance liquid chromatography are part of the analytical vocabulary, not a substitute for full validation.

Good manufacturing practice supports consistent lots, while regulatory compliance governs whether those lots can be moved into clinical trials. An investigational new drug package may require manufacturing information, chemistry data, safety studies, and a protocol that addresses cardiotoxicity and QT prolongation. The FDA has not approved ibogaine as a medicine.

Health Canada and the FDA each have distinct regulatory systems. Health Canada scrutiny and FDA expectations do not transform an unregulated product into a clinical supply merely because its label cites “GMP.” The facility, process, documentation, and intended use must be evaluated together.

A finished drug product development announcement shows how companies describe the handoff from supply to formulation. It is a useful distinction: securing material is not the same as completing drug development.

Another company-reported account, the strategic ibogaine manufacturing update, should likewise be read as an announcement about intended capacity and regulatory positioning, not as a clinical claim.

Unregulated clinics in jurisdictions such as Mexico and the Bahamas may operate within very different legal environments from a U.S. API facility. Their supply chain can include total alkaloid extracts, iboga extract, semi-synthetic material, or products of uncertain origin and purity. The label alone does not establish pharmaceutical-grade status.

This is one reason the phrase “who makes ibogaine” needs precision. A producer of total alkaloid material is not necessarily manufacturing a pure active pharmaceutical ingredient. A facility providing an API is not necessarily the sponsor of clinical trials. And a clinic may be neither a manufacturer nor a developer.

Variable extraction conditions, undocumented botanical raw material, and absent batch testing can obscure contaminants and dose. Where cardiotoxicity and QT prolongation are known concerns, that uncertainty is consequential. Quality control, controlled substance licensing, and clinical screening cannot be inferred from marketing language.

The discussion of DEA quota and manufacturing infrastructure highlights why formal U.S. production is often described in terms of registered operations rather than informal availability. The same distinction is relevant to anyone assessing supply claims for opioid use disorder research.